COMP <GO>
LMAT vs ABBV // RETURN ON INVESTED CAPITAL (ROIC)
LeMaitre Vascular Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: LMAT 9
— ABBV 4
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: ABBV
LAST: $85.27 (+2.90%) • MKT CAP: $1.95B
roic
14.70%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
roic
29.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LMAT VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LMAT | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 71.50% | 70.20% | +1.30 | LMAT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 14.70% | 29.00% | -14.30 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 28.3x | 33.3x | -5.00 | LMAT | /valuation <GO> |
| Free Cash Flow Yield | 4.17% | 3.47% | +0.70 | LMAT | /fcf-yield <GO> |
| Operating Margin | 27.20% | 24.60% | +2.60 | LMAT | /operating-margins <GO> |
| Net Profit Margin | 23.10% | 6.90% | +16.20 | LMAT | /net-margins <GO> |
| Revenue Growth (YoY) | 13.50% | 8.60% | +4.90 | LMAT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.93% | 2.27% | -1.34 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.30 | 5.33 | +1.97 | LMAT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | LMAT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.2 | 65.1 | -8.90 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 28.4x | 113.1x | -84.70 | LMAT | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.95B | $513.86B | -$511.91B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LMAT REV | ABBV REV | LMAT GROSS % | ABBV GROSS % | LMAT FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $249.6M | $61.16B | 71.5% | 70.2% | $81.3M | $17.82B |
| FY 2024 | $219.9M | $56.33B | 68.6% | 70.0% | $44.1M | $17.83B |
| FY 2023 | $193.5M | $54.32B | — | — | $36.8M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LMAT // BETA —
ABBV // BETA 1.15